Sevion Therapeutics Inc (SVON)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013606)
◆英語タイトル:Sevion Therapeutics Inc (SVON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013606
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:33
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Sevion Therapeutics Inc (Sevion), formerly Senesco Technologies, Inc. is a pharmaceutical company that discovers, develops and acquires product candidates for the treatment of cancer and immunological diseases. The company has developed protein nanocage system that allows delivery of nucleic acids and other payloads to target cells. Its product pipeline includes SVN-00, SVN-002, SVN-003, multiple GPCR targets and ion channel. The company’s SVN-002 is an antibody against an oncology target that has the potential to impact metastatic tumors, which include resistant to anti-VEGF treatments. Sevion is headquartered in San Diego, California, the US.

Sevion Therapeutics Inc (SVON) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Sevion Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Eloxx Pharma Raises Additional USD6 Million in Series C Financing 11
Partnerships 12
Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 12
Sevion Therapeutics to Form Joint Venture with Malvern Instruments 13
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 14
Sevion Therapeutics Enters into Research Agreement with Avidity NanoMedicines 15
Licensing Agreements 16
Fabrus Enters into Licensing Agreement with Scripps Research Institute 16
Equity Offering 17
Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 17
Senesco Raises USD3.5 Million in Private Placement of Shares upon Exercise of Warrants 18
Senesco Raises USD5.4 Million in First Tranche of Private Placement of Units 19
Senesco Technologies Completes Private Placement Of Shares For US$1.7 Million 20
Senesco Technologies Completes Private Placement Of Shares For US$1.25 Million 21
Senesco Technologies Completes Private Placement Of Shares For US$3 Million 22
Senesco Technologies Completes Second Tranche Of Private Placement Of Shares For US$1 Million 23
Senesco Technologies Completes Second Tranche Of Private Placement For US$1.65 Million 25
Acquisition 26
Sevion Therapeutics to Acquire Eloxx Pharma 26
Senesco Technologies Completes Acquisition of Fabrus 27
Sevion Therapeutics Inc – Key Competitors 28
Sevion Therapeutics Inc – Key Employees 29
Sevion Therapeutics Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Corporate Communications 31
Sep 26, 2017: Eloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer 31
Mar 10, 2016: Harlan Waksal, M.D. resigns as Chairman of the Board of Sevion Therapeutics 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List of Tables
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Sevion Therapeutics Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Sevion Therapeutics Inc, Medical Devices Deals, 2011 to YTD 2017 9
Sevion Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Eloxx Pharma Raises Additional USD6 Million in Series C Financing 11
Tetragenetics Enters into Agreement with arGEN-X, Crystal Biosciences and Sevion Therapeutics 12
Sevion Therapeutics to Form Joint Venture with Malvern Instruments 13
Sevion Therapeutics Enters into Discovery Agreement with CNA Development 14
Sevion Therapeutics Enters into Research Agreement with Avidity NanoMedicines 15
Fabrus Enters into Licensing Agreement with Scripps Research Institute 16
Sevion Therapeutics Raises USD6.6 Million in Private Placement of Units 17
Senesco Raises USD3.5 Million in Private Placement of Shares upon Exercise of Warrants 18
Senesco Raises USD5.4 Million in First Tranche of Private Placement of Units 19
Senesco Technologies Completes Private Placement Of Shares For US$1.7 Million 20
Senesco Technologies Completes Private Placement Of Shares For US$1.25 Million 21
Senesco Technologies Completes Private Placement Of Shares For US$3 Million 22
Senesco Technologies Completes Second Tranche Of Private Placement Of Shares For US$1 Million 23
Senesco Technologies Completes Second Tranche Of Private Placement For US$1.65 Million 25
Sevion Therapeutics to Acquire Eloxx Pharma 26
Senesco Technologies Completes Acquisition of Fabrus 27
Sevion Therapeutics Inc, Key Competitors 28
Sevion Therapeutics Inc, Key Employees 29
Sevion Therapeutics Inc, Subsidiaries 30

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Sevion Therapeutics Inc (SVON)-製薬・医療分野:企業M&A・提携分析(Sevion Therapeutics Inc (SVON) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆